ROFL Anyone paying attention to measured in kilograms ?
Happy April ! “Fools” -- J. Hellenthal The fact that there's a highway to Hell but only a stairway to Heaven says a lot about anticipated traffic volume. > On Apr 1, 2021, at 14:42, Carlos Alvarez <[email protected]> wrote: > > > Right? Where do they find all these blind doctors? > > >> On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <[email protected]> >> wrote: >> Maybe they should open their eyes instead of doing a double-blind study! >> LOL! >> >> MARY LOU CAREY >> BackUP Telecom Consulting >> Office: 615-791-9969 >> Cell: 615-796-1111 >> >> On 2021-04-01 02:27 PM, Hiers, David wrote: >> > No AI here... This is classic, small-batch, hand-crafted, free-range, >> > organic, gluten-free content. >> > >> > >> > David >> > >> > >> > -----Original Message----- >> > From: VoiceOps <[email protected]> On Behalf Of Alex >> > Balashov >> > Sent: Thursday, April 1, 2021 12:18 PM >> > To: Brandon Svec <[email protected]> >> > Cc: [email protected] >> > Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ >> > >> > Let me make sure I understand your question correctly: it is your >> > belief or conjecture that this press release was automatically >> > generated by a machine learning system? >> > >> > — >> > Sent from mobile, with due apologies for brevity and errors. >> > >> >> On Apr 1, 2021, at 3:10 PM, Brandon Svec <[email protected]> >> >> wrote: >> >> >> >> GPT-3? Happy April Fools Day. >> >> >> >> Brandon >> >> >> >>> On Mar 31, 2021, at 9:47 PM, Alex Balashov >> >>> <[email protected]> wrote: >> >>> >> >>> For immediate release: >> >>> >> >>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership >> >>> with Posner | Palner Pharmaceuticals, are pleased to announce the >> >>> eagerly anticipated start of Phase III clinical trials of Kamailio >> >>> DMQ module replication. >> >>> >> >>> In this stage of the investigation of the promising replication >> >>> scheme, which was developed in record time, DMQ will be tested in a >> >>> rigourous, double-blind, controlled CI/CD process for large-scale >> >>> efficacy and continually monitored for safety in shorter and longer >> >>> terms. >> >>> >> >>> The now-concluded second phase established basic safety and Phase 2b >> >>> entailed a dose-finding study for the optimal number of batched >> >>> `dmq_usrloc` contacts per kilogram of cloud computing resource. >> >>> >> >>> The main cohort of the main sequence of the Phase III trial will >> >>> enroll 380 randomly selected, statistically representative Floridian >> >>> SIP registrars and >> >>> 5700 SIP dialogs, also in the state of Florida. When asked about the >> >>> disparity in the number of registrars versus dialogs, Alex Balashov >> >>> of Evariste said, "It is reflective of the small number of SIP >> >>> registrars in Florida; not to be indelicate, but consider the median >> >>> age of the population." >> >>> >> >>> As previously remarked upon in proceedings of the World SIP >> >>> Organisation (WSO), the choice of Florida as a venue attracted some >> >>> questions. We asked Fred Posner of Posner | Palner about the clinical >> >>> background informing this choice of replication study cohort: >> >>> >> >>> "Florida is a good place to find eventual consistency failures; the >> >>> open climate and reluctance to accept traditional data integrity >> >>> science would have sealed the deal, but when people started to drink >> >>> bleach here, I saw an opportunity." >> >>> >> >>> Evariste and Posner | Palner are aiming for a US Food & Drug >> >>> Administration EUA (Emergency Use Authorisation) for DMQ replication >> >>> as a prophylactic data redundancy and failover measure to ward off >> >>> the development of moderate to severe viral Sonus Haemorrhagic Fever >> >>> symptoms. >> >>> >> >>> Phase II studies have painted a promising a picture of the DMQ >> >>> architecture's ability to reduce moderate to severe symptoms and >> >>> associated 28-day mortality by more than 90%, albeit over a small >> >>> sample size and in enterprise patients with known pre-existing >> >>> comorbidities such as Session Border Controller and BroadSoft >> >>> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster >> >>> quantums of broader efficacy, including efficacy for localised >> >>> outbreaks of small to medium business softswitch. >> >>> >> >>> Of the control group, Balashov said, "They will receive a standard >> >>> pipe-to-/dev/null placebo protocol, but with identical '200 OK' >> >>> confirmation messages. We proudly developed this approach in early >> >>> 2020 in consultation with the highest levels of the Trump >> >>> presidential administration; it is called TENP, or 'The Emperor's New >> >>> Potion.' It is a successor to that administration's previous approved >> >>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives." >> >>> >> >>> Despite speculative autism and packet fragmentation claims by Florida >> >>> Governor Ron DeSantis, Balashov was quick to provide reassurance >> >>> about side effects from DMQ in the Phase III trial. >> >>> >> >>> "The incidence of severe allergies to plain-text UDP was within >> >>> standard deviation over the mean for all insecure replication, and >> >>> there's support for other transports on the way. Anyway, we have a >> >>> robust adverse effects reporting system in our issue tracker and >> >>> solid surveillance. Don't let partisan politics dissuade you from >> >>> allowing request lines with the KDMQ method." >> >>> >> >>> Other industry sources have reported that DMQ is not the only >> >>> replication investigation undertaken by Evariste and Posner | Palner, >> >>> although it is the only prophylactic suitable for the early infection >> >>> development and inflammatory phases of a broad class of SBC-complex >> >>> syndromes typically afflicting service providers. A recent IETF >> >>> preprint by the same authors has shown high-quality preliminary data >> >>> suggesting statistically significant improvement in morbidity >> >>> outcomes from Perimeta and Nokia via a later-stage therapeutic >> >>> intervention with a monoclonal, monorepo Github cocktail administered >> >>> intravenously. >> >>> >> >>> >> >>> -- >> >>> Alex Balashov | Principal | Evariste Systems LLC >> >>> >> >>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) >> >>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ >> >>> _______________________________________________ >> >>> VoiceOps mailing list >> >>> [email protected] >> >>> https://puck.nether.net/mailman/listinfo/voiceops >> > _______________________________________________ >> > VoiceOps mailing list >> > [email protected] >> > https://puck.nether.net/mailman/listinfo/voiceops >> > >> > ---------------------------------------------------------------------- >> > This message and any attachments are intended only for the use of the >> > addressee and may contain information that is privileged and >> > confidential. If the reader of the message is not the intended >> > recipient or an authorized representative of the intended recipient, >> > you are hereby notified that any dissemination of this communication >> > is strictly prohibited. If you have received this communication in >> > error, notify the sender immediately by return email and delete the >> > message and any attachments from your system. >> > _______________________________________________ >> > VoiceOps mailing list >> > [email protected] >> > https://puck.nether.net/mailman/listinfo/voiceops >> _______________________________________________ >> VoiceOps mailing list >> [email protected] >> https://puck.nether.net/mailman/listinfo/voiceops > _______________________________________________ > VoiceOps mailing list > [email protected] > https://puck.nether.net/mailman/listinfo/voiceops
_______________________________________________ VoiceOps mailing list [email protected] https://puck.nether.net/mailman/listinfo/voiceops
